Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

134 results about "Hematological Diseases" patented technology

Protein-based delivery system

PCT designated stage expiredWO2025019713A2Connective tissue peptidesAntibody mimetics/scaffoldsElastin like polypeptidesRespiratory disease
Provided herein are elastin-like polypeptides, endosomal escape peptides, and compounds comprising an elastin-like polypeptide chemically or recombinantly conjugated to one or more endosomal escape peptides. Also provided herein are compositions comprising a compound provided herein and an agent, methods of delivering an agent, and methods of treating or preventing a disease (e.g., a cardiovascular disease, a lung or respiratory disease, a musculoskeletal disease, a hematological disease, an immune disorder, an infectious disease, a genetic disease, cancer, a neurological disease, a psychiatric disorder, a metabolic disorder, or an inflammatory disease).
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC

Antibodies specifically binding to MASP3 and multispecific antibodies specifically binding to MASP3 and MASP2

The invention relates to the field of biological medicine, in particular to a specific recognition MASP3 antibody and application thereof, and the antibody has high human MASP3 affinity and alternative pathway inhibitory activity. In addition, the invention also relates to a multispecific antibody which specifically binds to MASP3 and MASP2, as well as a pharmaceutical composition comprising an antibody which specifically binds to MASP3 or a multispecific antibody which specifically binds to MASP3 and MASP2, the antibody or the composition is used for preparing a medicament for treating autoimmune diseases, transplantation-related diseases, inflammatory diseases, hematological diseases, coagulation diseases, angiogenesis-dependent diseases and / or virus infectious diseases.
Owner:STAIDSON (BEIJING) BIOPHARMACEUTICALS CO LTD

(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
Owner:PHARVARIS GMBH

Novel compounds

The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder:wherein RA, RB, RC and RD, X, m and n are as defined herein.
Owner:SITRYX THERAPEUTICS LTD

Cyclic compound as well as pharmaceutical composition and application thereof

The invention provides a cyclic compound with a structure as shown in a formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule of the cyclic compound, and a pharmaceutical composition and application of the cyclic compound or the pharmaceutically acceptable salt or the stereoisomer or the prodrug molecule of the cyclic compound. The compound can be used as a protein kinase inhibitor, has very strong inhibitory activity on FLT3 mutant kinase, has very strong proliferation inhibitory activity on Ba / F3-FLT3-ITD and stable strain cells containing drug-resistant point mutation, can inhibit proliferation, migration and invasion of various tumor cells, and especially can overcome the drug resistance of existing clinical drugs. The cyclic compound provided by the invention can be used for preparing medicines for preventing or treating FLT3 tyrosine kinase mediated diseases (such as hematological malignancies), and can be used for treating various hematological malignancies of human beings and other mammals. # imgabs0 #
Owner:JINAN UNIVERSITY

Cell classification and blood disease identification and verification cloud platform system based on microscopic image

The invention provides a microscopic image-based cell classification method and a blood disease identification and verification cloud platform system, and relates to the field of hematopoietic system detection, the system comprises a terminal AI processing system, a central server AI processing system and an on-demand interaction system, and the terminal AI processing system and the central server AI processing system jointly construct a two-stage intelligent identification system architecture. Through the cooperation of the above structures, the system has the following beneficial effects: 1, a two-stage AI frame is adopted, data congestion is reduced, the workload of a central server is reduced, and in addition, only necessary data is uploaded through segmented transmission of images and an on-demand interaction mechanism, so that the data transmission amount is reduced; 2, a deep learning technology is utilized to realize automatic analysis of blood cell sample and bone marrow sample images; and thirdly, a feedback mechanism is introduced, and a set of intelligent verification system for continuous learning and optimization is constructed through mutual fusion of professional experience of doctors and an advanced deep learning technology.
Owner:HUAZHONG UNIV OF SCI & TECH

CD7 and FAS double-gene knockout CD7 CAR-T cell as well as preparation method and application thereof

The invention discloses a CD7 and FAS double-gene knockout CD7 CAR-T cell and a preparation method and application thereof.By means of the method, the self-killing phenomenon of the CAR-T cell can be avoided, the cell amplification efficiency and the treatment effect can be improved, in addition, the survival ability and durability of the CAR-T cell can be remarkably enhanced, the method has remarkable advantages in treatment of T cell hematological malignancies, and the method is suitable for being used for treating T cell hematological malignancies. The method has a good application prospect and important conversion significance.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY +1

Bicyclic urea kinase inhibitors and uses thereof

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
Owner:THE BROAD INST INC +2

3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives, process for their synthesis, use

PendingCN122444688AOncologyMalignancy
The application discloses a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative and a synthesis method and application thereof, and relates to a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative which is a compound with the following general formula (I): wherein R1 is selected from,,,,,,,,, and R2 is selected from,,, and. The compound can significantly inhibit the proliferation of leukemia, multiple myeloma, lymphoma, breast cancer, liver cancer and the like at a low dose (nanomole), can effectively degrade IKZF1, IKZF3, BRD4, GSPT1 and CK1 alpha, and has the prospect of being developed into an anti-tumor drug. The application solves the problem that the existing malignant hematological disease treatment drugs have a high safety risk.
Owner:NANTONG QUNDING PHARMACEUTICAL TECHNOLOGY CO LTD +1

Use of ivermectin in the preparation of a medicament for treating immune thrombocytopenia

This invention discloses the application and method of a STAT1-targeting inhibitor in the treatment of immune thrombocytopenic purpura (ITP). It employs ivermectin, a STAT1 nuclear translocation inhibitor, and fludarabine, a STAT1 activation inhibitor. By injecting either the activation inhibitor or the nuclear translocation inhibitor, the platelet count in a mouse model of ITP is increased. Fludarabine, a fluorinated nucleotide analog of vidarabine, is non-radioactive and a small-molecule phosphorylation inhibitor. Ivermectin is a small-molecule inhibitor of nuclear translocation mediated by α / β1 introgression protein. Both have high bioavailability and are widely used to treat various hematological diseases with good safety profiles. Their application in treating ITP is safe, effective, and shows high compliance.
Owner:SUZHOU UNIV

Products and compositions

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as β-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
Owner:SILENCE THERAPEUTICS GMBH

Substituted tricyclic ligands for FK506-binding proteins for treatment of diseases

PendingEP4631947A1Organic active ingredientsNervous disorderHaematological disordersDisease
The present invention relates to compounds having a fused, substituted tricyclic scaffold and stereo-isomeric forms, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted tricyclic derivatives together with pharmaceutically acceptable carrier, excipient and / or diluents. Said substituted tricyclic derivatives have been identified as especially potent ligands of FK506 binding proteins (FKBPs), especially human FKBP12, FKBP12.6, FKBP51 and FKBP52 or bacterial homologs like LpMip, CtMip, CpMip, NgMip, KpMip, BpMip, TcMip, EcFKLB, EcFKPA, PaFKLB, PaFKPA, AbFKLB, AbFKPA, and are useful for treatment of diseases such as psychiatric, metabolic, infective, neurological and haematological disorders as well as pain and cancers and as anti-inflammatory drugs. Said substituted tricyclic derivatives may further be used as agents for inducing protein-protein interactions (PPIs) acting as molecular glues.
Owner:TECH UNIV DARMSTADT

Antibody capable of specifically recognizing MASP3 and application thereof

The invention relates to the field of biological medicine, in particular to a specific recognition MASP3 antibody and application thereof, and the antibody has high human MASP3 affinity and alternative pathway inhibitory activity. The antibody is used for preparing a medicament for treating autoimmune diseases, transplantation-related diseases, inflammatory diseases, hematological diseases, hemolytic diseases, angiogenesis-dependent diseases and / or virus infectious diseases.
Owner:STAIDSON (BEIJING) BIOPHARMACEUTICALS CO LTD

EGF-like module containing mucin-like hormone-like 2 (ERM2) binding agents and methods of use thereof

The present disclosure provides antibodies, antigen binding fragments thereof, and fusion proteins, including chimeric antigen receptors, that target EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2). Also provided herein are methods of using such antibodies, antigen binding fragments thereof, and fusion proteins, for treating hematopoietic malignancies or hematological diseases (e.g., acute myeloid leukemia, myelodysplastic syndrome).
Owner:SYZYGYMED INC

Blood disease AI diagnosis assisting system

The invention provides a blood disease AI diagnosis assisting system. The system comprises a data acquisition module used for acquiring multi-modal data; the feature extraction module is used for performing feature extraction on the multi-modal data based on a preset fusion feature extraction strategy to obtain fusion features; the scheme generation module is used for generating a reference scheme which corresponds to the fusion features and is used for blood disease auxiliary diagnosis through a preset diagnosis-assisting scheme generation strategy according to the fusion features; the score acquisition module is used for acquiring a score matrix; the evaluation module is used for determining a comprehensive score of the reference scheme as an evaluation result according to the score matrix; and the feedback adjustment module is used for adjusting hyper-parameters in a preset fusion feature extraction strategy and / or a preset diagnosis assisting scheme generation strategy according to the evaluation result. Therefore, the problem that the finally output reference pathology recognition result is inaccurate due to the fact that the data mode of pathology recognition is single in the traditional hematological disease assisted diagnosis and assisted teaching process can be solved.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV

Biomarkers of t cell reactivity

The present invention relates to a method for assessing a hematological disease in a sample of a subject, said method comprising (a) determining in said sample at least five biomarkers selected from the list consisting of GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA- DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA; and (B) thereby assessing said hematological disease. The present invention further relates to methods, systems, kits and databases related thereto.
Owner:DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS +1

Antibodies specific for CD38 and uses thereof

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

Phthalazine derivatives as pyruvate kinase modulators

The present invention relates to a compound of formula (I) which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one [Formula 1] or a salt and / or solvate thereof; and its use in the treatment or prevention of an inflammatory disease, a disease associated with an unwanted immune response, cancer, obesity, a diabetic disease, or a blood disorder.
Owner:SITRYX THERAPEUTICS LTD

Ionizable lipids for multiple organ targeting

Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and / or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue / cell).
Owner:MASSACHUSETTS INST OF TECH

System and method for collecting and analyzing data of patients with blood diseases

The present invention discloses a blood disease patient data collection and analysis system and method, and relates to the technical field of medical data management. The system includes a multi-dimensional collection module and a management analysis module. The multi-dimensional collection module is used to connect a medical consultation client, an electronic medical record system, and a clinical information system through a network, and a data set is formed by classification. The management analysis module constructs a new cluster or updates the cluster structure according to the patient data set. All clusters correspond to each different blood disease patient, and each cluster is configured with an independent consultation code. A single consultation code corresponds to all identity information, medical record information, and clinical treatment information of the same blood disease patient, so that intelligent management of patient data is achieved, which is not easy to make mistakes. The management analysis module analyzes and generates a medical consultation data group and a trend data group, integrates the treatment information of the same patient, analyzes the change trend of the patient's blood indicators before and after treatment, and generates an evaluation report in combination, which can make medical staff more efficient during medical consultation.
Owner:JILIN UNIVERSITY

RT-RAP primer probe set and kit for detecting blood virus

The application provides an RT-RAP primer probe set and kit for detecting blood viruses, and belongs to the technical field of molecular biology. The primer probe set comprises a primer probe set for detecting hepatitis B virus, and / or a primer probe set for detecting hepatitis C virus, and / or a primer probe set for detecting human immunodeficiency virus. The application adopts the detection means of RT-RAA and qPCR in sequence, and can simultaneously and rapidly detect hepatitis B virus, hepatitis C virus and human immunodeficiency virus in combination with the specific primer probe set, has higher sensitivity than ordinary qPCR, greatly shortens the reaction time, and has good specificity.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Methods for treatment of patients with myelodysplastic syndromes

Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematological disease or disorder such as multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The effective amount of the anti-CD33 targeting agent may be an amount sufficient to induce myeloconditioning or an amount to induce myeloablation. The methods may further include transplanting allogeneic stem cells to the patient after administration of the anti-CD33 targeting agent.
Owner:ACTINIUM PHARMACEUTICALS INC

Diarylheptanoid-based compounds for ex VIVO expansion of hematopoietic stem cell populations and a method thereof

The present invention relates to diarylheptanoid-based compounds and a method for inducing ex vivo expansion of hematopoietic stem cell populations. This method comprises incubating HSCs in a culture medium comprising diarylheptanoid-based compounds, leading to improved ex vivo expansion of HSCs and preservation of their major specific properties. This includes self-renewal and multilineage differentiation. These resultant enhancements demonstrate the potential of HSCs for use in treating hematological diseases and blood cancers prior to HSCT.
Owner:MAHIDOL UNIV

Traditional Chinese medicine composition for treating chemotherapy-related oral mucositis and preparation method and application thereof

PendingCN121927001ACompatibility scienceReflect the idea of ​​compatibilityAntipyreticHydroxy compound active ingredientsScrophulariaForsythia
The invention discloses a traditional Chinese medicine composition for treating chemotherapy-related oral mucositis and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6-12 parts of radix rehmanniae recen, 6-12 parts of radix ophiopogonis, 6-12 parts of radix scrophulariae, 6-12 parts of honeysuckle, 6-12 parts of fructus forsythiae, 3-7 parts of radix scutellariae, 1-3 parts of lotus plumule, 3-7 parts of mint and 3-7 parts of borneol. The composition has the effects of nourishing yin, clearing heat, astringing sores and promoting tissue regeneration, and clinical tests prove that the composition can remarkably reduce the occurrence rate of chemotherapy-related oral mucositis of hematological malignancy patients, relieve the damage degree of oral mucosa, shorten the lasting time of ulcer and pain and effectively improve clinical symptoms of traditional Chinese medicine, and is high in safety.
Owner:THE FIRST AFFILIATED HOSPITAL OF TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

Anti-HLA-dr igm isotype monoclonal antibody potentiating the activity of Anti-CD20 igg1 or igm isotype antibodies

The present invention relates to a novel anti-HLA-DR IgM isotype monoclonal antibody and to the use thereof alone or in addition to anti-CD20 IgG1 or IgM isotype antibodies, in the treatment of B-phenotype lymphoid hemopathies, and in particular of non-Hodgkin lymphoma B, chronic lymphocytic leukemia (CLL) and B-cell malignant lymphoid hemopathies in general.
Owner:CENT NAT DE LA RECH SCI (C N R S) +5

Visualization method for rapidly detecting bovine babesiosis and application thereof

The invention belongs to the technical field of biological detection, and provides a visualization method for rapidly detecting bovine babesia disease and application of the method. Specific SBP2 multi-copy conservative genes of bovine babesia are targeted, high-specificity ERA primers are designed, an ERA-CRISPR / Cas12a two-stage signal amplification system is established, specific recognition is conducted on amplification products through a CRISPR / Cas12a system, and the specific Babesia disease is detected. And activating a fluorescence signal. Results show that the method has no cross reaction on five common blood pathogens such as babesia vole and the like, the detection sensitivity for the babesia bovis reaches 10 copies / mu L, and on-site visual diagnosis can be completed within 40 minutes.
Owner:XINJIANG AGRI UNIV

Compounds and compositions for the treatment of hematological disorders

The present invention relates to compounds and compositions for the treatment of hematological disorders. The present invention provides methods for the treatment of hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.
Owner:ORIGEN ONCOLOGY CO LTD

Traditional Chinese medicine composition for treating hematological malignancy spleen megaly and preparation method of traditional Chinese medicine composition

The invention discloses a traditional Chinese medicine composition for treating hematological malignancy and splenic enlargement and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials: cinnamon, rhizoma arisaematis, fructus gleditsiae, borneol, ferula asafetida, clove and green pepper. The traditional Chinese medicine has the advantages of scientific and reasonable component compatibility, abundant raw materials, simple preparation method, obvious treatment effect and no toxic or side effect. The pharmaceutical composition disclosed by the invention has the effects of warming yang, reducing phlegm, softening hardness and dissipating binds, can effectively control hematological malignancy spleen enlargement, improve abdominal distension and discomfort symptoms of patients and relieve pains of the patients, and has remarkable social and economic benefits.
Owner:THE FIRST AFFILIATED HOSPITAL OF TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

Treatment of hemorrhage and hemorrhagic disorders by high intensity focused ultrasound stimulation of the spleen

Devices and methods for reducing or limiting bleeding in an animal by stimulating the spleen with focused ultrasound (FUS). The devices and methods can be used to treat blood disorders such as hemophilia, or to reduce bleeding during surgery or due to trauma. The methods can be administered to a patient non-invasively by applying ultrasound energy transcutaneously.
Owner:THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH